Can-Fite BioPharma Announces Successful Completion of Its Public Offering
2/5/2013 10:16:06 AM
More...
|
Can-Fite BioPharma Announces 2013 Milestones and Corporate Strategy
1/29/2013 11:19:05 AM
More...
|
Can-Fite BioPharma Shifts Drug Manufacturing to China
1/22/2013 11:06:01 AM
More...
|
Can-Fite BioPharma to Develop a Drug for the Treatment of Sexual Dysfunction
11/13/2012 9:46:59 AM
More...
|
Can-Fite BioPharma Receives Quotation Clearance for Its Level 1 ADRs
11/5/2012 12:30:52 PM
More...
|
Interim Analysis Supports Continuation of Can-Fite BioPharma's Phase 2/3 Psoriasis Clinical Study With CF101
10/9/2012 9:38:10 AM
More...
|
Can-Fite BioPharma Begins Trading in U.S. through Launch of ADRs
10/4/2012 11:11:12 AM
More...
|
FDA Grants Orphan Drug Status for CF102 for the Treatment of Hepatocellular Carcinoma to Can-Fite BioPharma
2/23/2012 8:39:11 AM
More...
|
Can-Fite BioPharma Announces Successful Results of its Phase I/II Liver Cancer Study with its CF102 Drug; the Study Achieved the Primary and Secondary Endpoints
1/3/2012 9:22:06 AM
More...
|
Can-Fite BioPharma Announces the Initiation of Patient Enrolment for the Phase 2/3 Psoriasis Study with its Lead Drug CF101
8/1/2011 10:51:16 AM
More...
|
|